scPharmaceuticals ended the second quarter of 2023 with $102.9M in cash, cash equivalents and short-term investments, compared to $118.4m as of December 31, 2022. “The second quarter of 2023 was our first full quarter of FUROSCIX commercial availability and we continue to experience positive underlying demand trends, as reflected in both unique prescribers and total prescriptions written, suggesting that FUROSCIX continues to be well received in the market,” stated John Tucker, President, and CEO of scPharmaceuticals. “In response to these positive trends, we continue to refine our sales organization, and we added 10 additional territories toward the end of Q2, increasing our total organization to 54 territories, that will contribute to our outreach efforts beginning in Q3. We are still in the very early stages of developing the outpatient subcutaneous diuretic market and we remain encouraged by the high level of patient satisfaction, physician engagement, and doses per prescription. These key metrics give us the conviction to add additional territories opportunistically as warranted to maximize geographic coverage and patient access to FUROSCIX.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SCPH:
- scPharmaceuticals Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update
- SCPH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- scPharmaceuticals to Announce Second Quarter 2023 Financial Results on Thursday, August 10, 2023
- scPharmaceuticals announces positive Type C feedback from FDA on FUROSCIX
- scPharmaceuticals reports inducement grants under Nasdaq listing rule